Journals / Journal of Medicine and Palliative Care / 2026 / Volume: 7 Issue: 4

Clinical, biochemical, radiological, and histopathological characteristics of large and giant sellar masses: a single-centre study

Ekin Yiğit Köroğlu(Ankara Bilkent Şehir Hastanesi, Endokrinoloji ve Metabolizma Bilim Dalı)0000-0003-3895-5817
Muhammed Saçıkara(Ankara Bilkent Şehir Hastanesi)0000-0002-1689-338X
Didem Özdemir(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7826-9059
Narin Nasıroğlu İmga(Ankara Bilkent Şehir Hastanesi)0000-0001-8013-230X
Oya Topaloğlu(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-2501-935X
Reyhan Ersoy(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-7437-1176
Bekir Çakır(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7526-8827
Pages
—
Publication Date
2026-08-15
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings support a thorough hormonal and radiological work-up at diagnosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Large and giant sellar masses are uncommon but clinically important lesions.
📊
Key Findings & Data:We aimed to describe the clinical, biochemical, radiological, and histopathological features of patients with a sellar mass ≥30 mm and to examine differences by gender and age.
💡
Conclusion & Impact:These findings support a thorough hormonal and radiological work-up at diagnosis.
🔬Design:Research Article
📍Scope:2021 Verileri
⚙️Variables:Pituitary neoplasms · sellar mass · hypopituitarism

Abstract

Aims: Large and giant sellar masses are uncommon but clinically important lesions. We aimed to describe the clinical, biochemical, radiological, and histopathological features of patients with a sellar mass ≥30 mm and to examine differences by gender and age. Methods: In this single-centre, retrospective study, we screened 5,142 contrast-enhanced pituitary magnetic resonance imaging reports belonging to 3,414 patients evaluated between December 2021 and December 2024. Patients aged ≥18 years with a sellar mass ≥30 mm in maximum diameter were included. Clinical, biochemical, radiological, and histopathological data were collected and analysed. Results: Seventy-two patients were included (40 male, 32 female; mean age 55.4±14.4 years). The median maximum diameter was 34.0 (30.0-55.0) mm. Optic chiasm compression (81.9%), cavernous sinus invasion (79.2%), and sphenoid sinus invasion (54.2%) were frequent. Half of the patients (50.0%) had at least one anterior pituitary hormone deficiency, and 22.2% had panhypopituitarism. Thirteen tumours (18.1%) were functioning, most often causing acromegaly. Pituitary adenoma was the dominant histopathological diagnosis (90.3%), and gonadotroph adenomas predominated (69.6%). Male had larger tumours than female, by both maximum diameter (38.0 vs 34.0 mm; p=0.007) and volume (14.3 vs 10.5 cm³; p=0.002). Functioning tumours were more common in younger patients (p=0.024), whereas sphenoid sinus invasion was more frequent with advancing age (p=0.002). Conclusion: Large and giant sellar masses are usually invasive, compress the optic chiasm, and are accompanied by hypopituitarism in half. Most are non-functioning gonadotroph adenomas. Male present with larger tumors, and functioning tumors cluster in younger patients. These findings support a thorough hormonal and radiological work-up at diagnosis.

🔖

Cite This Article

Köroğlu, E. Y., Saçıkara, M., Özdemir, D., İmga, N. N., Topaloğlu, O., Ersoy, R., Çakır, B. (2026). Clinical, biochemical, radiological, and histopathological characteristics of large and giant sellar masses: a single-centre study. Journal of Medicine and Palliative Care, Volume: 7 Issue: 4. https://doi.org/10.47582/jompac.1976697

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Kostopoulos G, Makri ES, Divaris E, Efstathiadou ZA. Sellar lesions: novel aspects in diagnosis and management. Cancers (Basel). 2026;18(6): 1029. doi:10.3390/cancers18061029
  2. Iglesias P, Arcano K, Triviño V, et al. Giant non-functioning pituitary adenoma: clinical characteristics and therapeutic outcomes. Exp Clin Endocrinol Diabetes. 2021;129(04):309-313. doi:10.1055/a-1017-3288
  3. Makarenko S, Alzahrani I, Karsy M, Deopujari C, Couldwell WT. Outcomes and surgical nuances in management of giant pituitary adenomas: a review of 108 cases in the endoscopic era. J Neurosurg. 2022;137(3):635-646. doi:10.3171/2021.10.JNS21659
  4. Gaillard S, Adeniran S, Villa C, et al. Outcome of giant pituitary tumors requiring surgery. Front Endocrinol (Lausanne). 2022;13:975560. doi:10.3389/fendo.2022.975560
  5. Carretti AL, Kaparounaki C, Raverot G. Aggressive and malignant pituitary tumours: does the sex matter? Pituitary. 2026;29(2):48. doi:10.1007/s11102-026-01656-y
  6. Dzialach L, Sobolewska J, Zak Z, Respondek W, Witek P. Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment. Front Endocrinol (Lausanne). 2024; 15:1338345. doi:10.3389/fendo.2024.1338345
  7. Ko C-C, Chang C-H, Chen T-Y, et al. Solid tumor size for prediction of recurrence in large and giant non-functioning pituitary adenomas. Neurosurg Rev. 2022;45(2):1401-1411. doi:10.1007/s10143-021-01662-7
  8. Iglesias P, Rodríguez Berrocal V, Díez JJ. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. Endocrine. 2018;61(3):407-421. doi:10.1007/s12020-018-1645-x
  9. Pelsma IC, Verstegen MJ, de Vries F, et al. Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. Pituitary. 2020;23(4): 417-429. doi:10.1007/s11102-020-01044-0
  10. Sinha S, Sharma B. Giant pituitary adenomas—an enigma revisited. Microsurgical treatment strategies and outcome in a series of 250 patients. Br J Neurosurg. 2010;24(1):31-39. doi:10.3109/02688690903370305
  11. Al Argan R, Ramadhan A, Agnihotram RV, Chankowsky J, Rivera J. Baseline MRI findings as predictors of hypopituitarism in patients with non-functioning pituitary adenomas. Endocr Connect. 2021;10(11):1445-1454. doi:10.1530/EC-21-0386
  12. Asa SL, Ezzat S, Mete O. Clinical integration and application of the 2022 WHO pituitary tumor classification. Neurooncol Adv. 2025; 7(Supplement_1):i10-i16. doi:10.1093/noajnl/vdae145
  13. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol. 2022;33(1):6-26. doi:10.1007/s12022-022-09703-7
  14. Castellanos LE, Gutierrez C, Smith T, Laws ER, Iorgulescu JB. Epidemiology of common and uncommon adult pituitary tumors in the US according to the 2017 World Health Organization classification. Pituitary. 2022;25(1):201-209. doi:10.1007/s11102-021-01189-6
  15. Valassi E, Biller BM, Klibanski A, Swearingen B. Clinical features of nonpituitary sellar lesions in a large surgical series. Clin Endocrinol (Oxf). 2010;73(6):798-807. doi:10.1111/j.1365-2265.2010.03881.x
  16. McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA. Demographic differences in incidence for pituitary adenoma. Pituitary. 2011;14(1):23-30. doi:10.1007/s11102-010-0253-4
  17. Park S, Kang H, Kim Y, Kim J. Different tumor growth pattern of clinically nonfunctioning pituitary neuroendocrine tumor according to sex and age: a longitudinal study. J Endocrinol Invest. 2024;47(8):1911-1921. doi:10.1007/s40618-024-02303-8
  18. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery. 2007;60(6):993-1004. doi:10.1227/01.NEU.0000255459.14764.BA